These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 14512572

  • 1. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.
    Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, Hilt S, Martin L, Vita C, Zhu P, Roux KH, Vojtech L, C Montefiori D, Donnelly J, Ulmer JB, Barnett SW.
    J Virol; 2003 Oct; 77(20):11244-59. PubMed ID: 14512572
    [Abstract] [Full Text] [Related]

  • 2. Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates.
    Srivastava IK, Kan E, Sun Y, Sharma VA, Cisto J, Burke B, Lian Y, Hilt S, Biron Z, Hartog K, Stamatatos L, Diaz-Avalos R, Cheng RH, Ulmer JB, Barnett SW.
    Virology; 2008 Mar 15; 372(2):273-90. PubMed ID: 18061231
    [Abstract] [Full Text] [Related]

  • 3. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.
    Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, Coates SR, Leung L, Wininger M, Donnelly JJ, Ulmer JB, Barnett SW.
    J Virol; 2002 Mar 15; 76(6):2835-47. PubMed ID: 11861851
    [Abstract] [Full Text] [Related]

  • 4. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT, Chamcha V, Kesavardhana S, Shen X, Beaumont D, Das R, Wyatt LS, LaBranche CC, Stanfield-Oakley S, Ferrari G, Montefiori DC, Moss B, Tomaras GD, Varadarajan R, Amara RR.
    J Virol; 2018 Mar 01; 92(5):. PubMed ID: 29237847
    [Abstract] [Full Text] [Related]

  • 5. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, Binley JM, Stamatatos L.
    J Virol; 2006 Sep 01; 80(17):8745-62. PubMed ID: 16912322
    [Abstract] [Full Text] [Related]

  • 6. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR, Stamatatos L.
    J Virol; 2001 Jun 01; 75(12):5526-40. PubMed ID: 11356960
    [Abstract] [Full Text] [Related]

  • 7. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL, Liao HX.
    AIDS Res Hum Retroviruses; 2005 Jan 01; 21(1):58-67. PubMed ID: 15665645
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
    Lian Y, Srivastava I, Gómez-Román VR, Zur Megede J, Sun Y, Kan E, Hilt S, Engelbrecht S, Himathongkham S, Luciw PA, Otten G, Ulmer JB, Donnelly JJ, Rabussay D, Montefiori D, van Rensburg EJ, Barnett SW.
    J Virol; 2005 Nov 01; 79(21):13338-49. PubMed ID: 16227256
    [Abstract] [Full Text] [Related]

  • 9. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R.
    J Virol; 2006 Feb 01; 80(3):1414-26. PubMed ID: 16415019
    [Abstract] [Full Text] [Related]

  • 10. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
    Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L.
    J Virol; 2003 Feb 01; 77(4):2310-20. PubMed ID: 12551968
    [Abstract] [Full Text] [Related]

  • 11. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.
    Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Barnett SW, Srivastava IK.
    Virology; 2006 Aug 15; 352(1):131-44. PubMed ID: 21894641
    [Abstract] [Full Text] [Related]

  • 12. A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies.
    Bibollet-Ruche F, Russell RM, Ding W, Liu W, Li Y, Wagh K, Wrapp D, Habib R, Skelly AN, Roark RS, Sherrill-Mix S, Wang S, Rando J, Lindemuth E, Cruickshank K, Park Y, Baum R, Carey JW, Connell AJ, Li H, Giorgi EE, Song GS, Ding S, Finzi A, Newman A, Hernandez GE, Machiele E, Cain DW, Mansouri K, Lewis MG, Montefiori DC, Wiehe KJ, Alam SM, Teng IT, Kwong PD, Andrabi R, Verkoczy L, Burton DR, Korber BT, Saunders KO, Haynes BF, Edwards RJ, Shaw GM, Hahn BH.
    mBio; 2023 Feb 28; 14(1):e0337022. PubMed ID: 36629414
    [Abstract] [Full Text] [Related]

  • 13. Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes.
    Kumar R, Ozorowski G, Kumar V, Holden LG, Shrivastava T, Patil S, Deshpande S, Ward AB, Bhattacharya J.
    J Biol Chem; 2017 Sep 22; 292(38):15849-15858. PubMed ID: 28743743
    [Abstract] [Full Text] [Related]

  • 14. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
    Gift SK, Leaman DP, Zhang L, Kim AS, Zwick MB.
    J Virol; 2017 Dec 15; 91(24):. PubMed ID: 28978711
    [Abstract] [Full Text] [Related]

  • 15. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
    Ching LK, Vlachogiannis G, Bosch KA, Stamatatos L.
    J Virol; 2008 Jan 15; 82(2):949-56. PubMed ID: 18003732
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
    Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA, Xiao P, Reddy S, Francella N, Sodora DL, Silvestri G, Cole KS, Villinger F, Robinson JE, Pulendran B, Hunter E, Collman RG, Amara RR, Derdeyn CA.
    J Virol; 2015 Aug 15; 89(16):8130-51. PubMed ID: 26018167
    [Abstract] [Full Text] [Related]

  • 18. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
    Castillo-Menendez LR, Witt K, Espy N, Princiotto A, Madani N, Pacheco B, Finzi A, Sodroski J.
    J Virol; 2018 Jun 15; 92(12):. PubMed ID: 29618643
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.